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The complications associated with acquiring and storing whole blood for transfusions have launched substantial efforts to develop 
a blood substitute. The history of these efforts involves a complicated mixture of science, ethics, and business. This review focuses 
on clinical trials of the three hemoglobin-based oxygen carriers (HBOC) that have progressed to Phase II or III clinical trials: He-
mAssist (Baxter; Deerfield, IL, US), PolyHeme (Northfield; Evanston, IL, US), and Hemopure (Biopure; Cambridge, MA, US). 
Published animal studies and clinical trials carried out in a perioperative setting have demonstrated that these products successfully 
transport and deliver oxygen, but all may induce hypertension and lead to unexpectedly low cardiac outputs. Overall, these studies 
suggest that HBOCs resulted in only modest blood saving during and after surgery, no improvement in mortality and an increased 
incidence of adverse reactions. To date, the results from these perioperative studies have not led to regulatory approval. All three 
companies instead chose to focus their efforts on large trials of trauma patients in the pre-hospital setting. 
Baxter abandoned the development of HemAssist after a trial in the U.S. was prematurely halted when the first 100 patients showed 
significantly increased mortality rates as compared to patients treated with blood products. Northfield’s PolyHeme trial demonstrated 
a non-significant trend towards increased mortality and a very modest reduction in the subsequent need for blood. The testing of 
Biopure’s Hemopure for trauma patients has been halted for several years because of FDA concerns over trial design and study 
justification. Ethical concerns have also been raised regarding the design and implementation of all HBOC clinical trials. 
Thus, the available evidence suggests that HemAssist, Polyheme, and Hemopure are associated with a significant level of cardio-
vascular dysfunction. The next generation of HBOCs remains under development.
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INTRODUCTION
Blood transfusions are a life saving intervention, but also 
have inherent side effects and dangers. Blood donated in the 
U.S. today is remarkably safe because of the sensitive assays 
used to detect blood-borne diseases. Despite this, allogeneic 
blood transfusion still carries a risk of exposure to blood 
borne pathogens, such as viral hepatitis and HIV. Blood is 
screened with nucleic acid amplification testing, which has 
reduced the risk of HIV transmission through donated blood 
to approximately one in 1.9 million.1 Another complication 
that can occur with blood transfusions is inaccurate 
cross-matching, which ran result in antigen binding and 
subsequent agglutination. Although the incidence of fatal 
ABO-incompatible transfusions is less than one in 1.5 
million transfusions, it remains the leading direct cause of 
deaths resulting from blood transfusion.2 
However, the greatest risk of transfusions may be 
the alterations they induce in recipients’ immunological 
function. Shortly after trauma resulting from accidents 
or major surgeries, an individual’s immune system is up-
regulated. Thus, trauma itself, along with transfusions, can 
cause cytokine release, including systemic inflammatory 
response.3 However, as time elapses after trauma has 
occurred, a patient’s immune function will become 
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down-regulated and additional transfusions can further 
depress neutrophil activity and put the patient at risk of 
infection. Repeated blood transfusions can lead to serious 
complications, as the incidence of multiple organ failure 
(MOF) increases with the amount of blood transfused. 4 This 
finding may result from a severe systemic inflammatory 
response caused by multiple blood transfusions.
Logistical and practical constraints may reduce blood 
availability and increase the cost of blood transfusions. 
Hospitals and blood banks often experience shortages 
of donated blood. Additionally, the ability to meet the 
need for blood in a mass casualty situation or in combat 
casualty care is often limited. Donated and stored red 
blood cells have a short stored shelf life (42 days) and 
must be stored in a refrigerated environment. Stored blood 
also loses 2,3-diphosphoglycerate (2,3-DPG) as time 
progresses, increasing its oxygen affinity and impairing 
oxygen unloading capacity in tissues. Thus, the biological 
limitations, side effects and logistical constraints of blood 
transfusions underscore the importance of developing a 
viable blood substitute.
For more than 100 years researchers have pursued the 
“Holy Grail” of trauma medicine: a blood substitute. The 
ideal blood substitute would retain all the functions of blood 
and none of the transfusion problems associated with blood. 
The term “blood substitute” does not accurately describe the 
current candidate products because they typically have only 
two limited functions: carrying and delivering oxygen and 
augmenting blood volume. Although no single product can 
yet imitate all the properties of blood, substantial progress 
has been made, especially in the development of hemoglobin 
based oxygen carriers (HBOCs). Although some products 
have come close, no HBOC has yet been approved for 
clinical use in the U.S. or Europe. This review focuses on 
the history and clinical trial results of the three HBOCs that 
have progressed to Phase II or III clinical trials: HemAssist, 
PolyHeme, and Hemopure.
Early History
Research exploring alternatives to blood began 
approximately 150 years ago. Searching for a blood substitute, 
T. Gaillard Thomas5 posited that intravenous infusion of cow’s 
milk, a process he termed “lacteal injections,” might have the 
potential to save lives. He justified his position by enumerating 
chemical similarities between lymphatic chyle and milk, 
emphasizing that both are fats that are emulsified in fluid. 
Thomas presented three case studies of moribund patients into 
whom he injected about 8 ounces of fresh cow’s milk. In these 
case studies, one patient survived and two died. He attributed 
their deaths to other complications unrelated to the lacteal 
injections and claimed the injections were safe provided that 
fresh milk was used. 
Despite Thomas’s claims, the development of blood 
substitutes logically turned to creating hemoglobin solutions, 
which were first clinically tested in the early 20th century. 
Hemoglobin’s oxygen carrying characteristics made it 
the logical choice for blood substitutes, but its uses came 
with unexpected consequences. Amberson et al. performed 
experiments in cats in which they completely replaced 
the animals’ blood with cell-free hemoglobin in lactated 
Ringer’s solution and showed that the solution could 
sustain life.6 However, the benefits were short-lived and the 
treatment caused significant renal damage. Despite these 
observations, the group performed clinical trials using a 
product containing hemoglobin in lactated Ringer’s solution, 
which unfortunately produced significant renal dysfunction 
in 5 of 14 patients.7 Amberson et al. abandoned their studies 
and concluded that hemoglobin solutions required further 
development because of the associated renal toxicity and 
vascular hypertension. In the 1950s, the U.S. Navy treated 
47 anemic and febrile sailors with one or more infusions 
of free hemoglobin solutions.8 Seventeen sailors became 
hypertensive and 12 out of 52 infusions led towards signs 
of renal problems. The remaining sailors who did not have 
renal problems experienced other untoward side effects. 
Renal toxicity seemed to be caused by obstruction of 
renal tubules as a result of hemoglobin and red cell stroma 
deposition, impaired renal function linked with heme 
pigment deposition, and decreased renal blood flow due to 
hemoglobin-induced vasoconstriction.8
Because of the evidence that hemoglobin-based blood 
substitutes were associated with renal toxicity, interest 
in these solutions waned and several years passed before 
useable stroma free hemoglobin solutions were developed. 
Ultra-purification techniques that allowed for the removal 
of stroma and other cellular debris from these compounds 
largely solved the problem of renal toxicity. However, new 
problems emerged. Native tetrameric hemoglobin, when 
removed from the red cell, breaks down into dimers, which 
are rapidly cleared by glomerular filtration, resulting in a 
short vascular half-life. Furthermore, free hemoglobin has 
reduced contact with phosphates, causing the P50 curve to 
shift to the left, resulting in hemoglobin with a high oxygen 
affinity and limited oxygen unloading. 
To address these limitations, a variety of approaches 
were used to molecularly stabilize and chemically 
modify hemoglobin. In the late 1960s, researchers for 
the U.S. Army offered a new and promising hemoglobin 
solution. Bunn and Jandl9 crosslinked hemoglobin with 
bis (N-maleimidomethyl) ether (BME), prolonging its 
intravascular retention. Crosslinking reduced the hemoglobin 
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molecule’s tendency to form dimers, thus decreasing its renal 
filtration and clearance. 
Other investigators produced hemoglobin that had 
been chemically modified at the 2,3-DPG site, the amino 
terminal group, or internally10, 11 in an attempt to prevent 
hemoglobin from disassociating into the αβ dimers and as 
a means of restoring the P50 to near-normal levels. Using a 
different approach, Bonsen et al.12 produced a hemoglobin 
that was polymerized with glutaraldehyde, which prolonged 
its intravascular retention. Another modification approach 
involved the attachment of hemoglobin to a larger molecule, 
which caused it to stay within the vascular system for a 
longer period of time than non-modified hemogobin. In one 
study, hemoglobin coupled to dextran13 showed to support 
life in dogs and cats in the absence of red blood cells.14
Out of these and other suggested chemically modified 
hemoglobins, several products progressed to human studies 
and limited testing in human patients. However, only three 
advanced to Phase II and III trials in peer-reviewed journals. 
Our review focuses on these three products: HemAssist 
(Baxter), PolyHeme (Northfield), and Hemopure (Biopure). 
Although other HBOCs have been studied in clinical 
trials, the results have been under-reported to date. These 
products include Hemosol’s Hemolink and Somatogen’s 
Optro. Development of both products was reportedly halted 
due to increased rates of cardiac arrest. Both companies have 
ceased operations. In the following sections, we review the 
research and development process and results from the key 
clinical trials of HemAssist, PolyHeme, and Hemopure.
Methods of Selection
We sought to identify all Phase II and III clinical 
trials involving HemAssist, PolyHeme and Hemopure by 
searching Medline using the keywords for the commercial 
and research names of these products (specifically, we used 
the terms “HemAssist,” “DCLHb,” “PolyHeme,” “SFH-P,” 
“Hemopure,” and “HBOC-201”). Additionally, we also 
reviewed company press releases to find information 
regarding recent trials and company efforts. We omitted 
Phase I clinical trials in healthy volunteers, case reports, 
trials with no control group, trials with fewer than 40 
participants, and interim studies that were subsequently 
published in full. We extracted data regarding patient 
populations, HBOC dosage, the control group dosage and 
key results for all included studies.
Corporate History and Initial Research and  
Development
DCLHb/HemAssist (Baxter): In the 1980s, researchers 
at the Letterman Army Institute of Research (LAIR) began 
working on a blood substitute similar to the previously 
studied solutions containing glutaraldehyde-treated 
hemoglobin. These scientists eventually created diaspirin 
cross-linked hemoglobin (DCHb). In order to move their 
product to the larger scale for clinical trial lots, competitive 
bids were solicited from private industry and DCLHb was 
eventually licensed to Baxter Healthcare in 1985. 
The formulation was called αα-Hb by the U.S. Army 
and DCLHb or HemAssist by Baxter. The source of 
hemoglobin was outdated human red blood cells that were 
pooled, washed, lysed and filtered. The product was then 
deoxygenated, crosslinked with bis(3,5-dibromosalicyl)
fumarate, and reoxygenated. One unit of Baxter’s DCLHb 
was made with 25 g hemoglobin in 250 ml, resulting in 
a concentration of 10 g/dL. DCLHb solutions exhibited 
a P50 of 32 mmHg, a colloid osmotic pressure (COP) of 
42 mmHg and a methemoglobin content of <5%.15 It also 
Table 1 - Properties of hemoglobin based oxygen carriers
Properties of Hemoglobin Based Oxygen Carriers
Characteristics
Products
DCLHb
(Baxter)15
SFH-P
(Northfield)21,23
HBOC-201
(Biopure)26
Solution Concentration (g/dL) 10 10 12-14
P50 (mmHg) 32 20-22 40
COP (mmHg) 42 20-25 25
Methemoglobin (%) <5 <5 <10
Average Weight (kDa) 64 150 250
Viscosity (cp) 1.2 1.9-2.2 1.3
In vivo Half-life (hrs) 6-12 24 19
Shelf-life (yrs) 1+ 1+ 3
Storage Temperature (°C) <5 4-8 2-30
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exhibits a long shelf life when stored in a freezer. Table 1 
lists additional characteristics of DCLHb.
Conflicts arose between the LAIR group and Baxter over 
direction of research and development and the two groups 
severed ties. Baxter Healthcare continued to develop the 
product, which they called HemAssist, and aggressively 
pursued animal studies and clinical trials. The U.S. Army 
continued to perform pre-clinical animal work with the 
αα-Hb formulation. A July 2007 Medline search using 
keywords “DCLHb” or “HemAssist” returned 29 clinical, 
114 animal and 8 in vitro studies. Overall, the results of the 
U.S. Army’s sponsored research were discouraging, while 
Baxter’s animal research suggested that HemAssist might 
have clinical efficiency. Baxter’s HemAssist then advanced 
through a series of Phase I clinical trials and became the first 
HBOC to advance to Phase II and III clinical trials.
No published study documented a difference between the 
U.S. Army’s αα-Hb and Baxter’s final HemAssist product. 
Baxter performed over a hundred animal studies and the 
U.S. Army published several studies, with some reports 
indicating that the product caused vasoconstriction. The U.S. 
Army sponsored studies that suggested the vasoconstriction 
was a severe limitation, but the Baxter studies found that 
HemAssist improved tissue oxygenation and hypothesized 
that clinical benefits might result from the vasoconstriction.16 
We discuss major clinical trials using DCLHb in the next 
section, Key Clinical Trials. 
SFH-P/PolyHeme (Northfield): Northfield Laboratories, 
located in Evanston, Illinois, was not established until 1985, 
although the developers of poly stroma-free hemoglobin 
(SFH-P, PolyHeme) began developing the formulation in 
1969 in conjunction with the U.S. Army.17 The U.S. Army 
funded initial studies and the company went public in 
1994. In contrast with Baxter, Northfield published little 
data from animal studies and performed only a few clinical 
trials. A July 2007 Medline search using keywords “SFH-P” 
or “PolyHeme” returned 10 clinical trials, 8 animal and 
3 in vitro studies. However, on closer examination of the 
references, only five studies presented clinical data. These 
studies provided sparse data regarding the physiological 
occurrences during infusion, but focused instead on 
reductions in the requirement for red blood cell (RBC) 
transfusions as a result of product usage. The only published 
animal studies on PolyHeme that included significant 
physiologic data were performed recently in independent 
experimental assessments of PolyHeme performed by 
the U.S. Army.18,19 Thus the scientific community had the 
opportunity to examine data from animal studies only after 
several clinical studies were performed.
The physiological effects of PolyHeme were largely 
unknown to the research community until these recent 
studies. Northfield reported that PolyHeme was devoid of 
the vasoconstrictive effects that was a noted side effect of 
the other HBOCs.20 Northfield reasoned that SFH-P did not 
result in the vasoconstrictive effects because the polymerized 
hemoglobin was too large to extravasate into the interstitial 
space, thus resulting in only limited binding of nitric oxide, 
which has vasodialatory effects.21 Deoxyhemoglobin has 
a high affinity for nitric oxide and thus readily binds it, 
subsequently depleting the amount of nitric oxide in the 
blood vessel and causing hypertension.22 In contrast to 
Northfield’s findings, both Baxter and Biopure reported 
vasoconstriction when testing variations of polymerized 
hemoglobin that were similar to SFH-P (Burhop K 2003, 
oral communication). Northfield’s clinical studies revealed 
only mild increases in systemic blood pressure, but did not 
include acute data on cardiac output, pulmonary pressures, 
calculated vascular resistances. Studies performed in 
independent U.S. Army laboratories demonstrated that 
PolyHeme exhibited vasoconstrictive properties and 
conferred no survival value in swine and rat models of 
hemorrhage.18,19
SFH-P is produced by crosslinking the stroma-free 
hemoglobin from outdated RBCs with glutaraldehyde 
and then pyridoxylating it. The product has a P50 of 20-22 
mmHg (compared to a normal RBC, which exhibits a P50 
of 26 mmHg). To obtain a COP that is near the normal 
value, the hemoglobin is polymerized with glutaraldehyde 
and all unreacted tetramer is then removed.21 One unit of 
SFH-P consists of 50 g of hemoglobin in 500 mL electrolyte 
solution, which is equivalent to less than 50% of the 
hemoglobin content in a typical unit of packed red blood 
cells (PRBCs). At 10 g/dL, the final product has a COP of 
20-25 mmHg. A molecule of SFH-P has an average weight 
of 150 kDa (range: 64 and 400 kDa). The viscosity is double 
that of saline. Methemoglobin accounts for less than 5% of 
the final product and the product is stable for at least a year, 
when stored at 4-8°C.21 Additional characteristics of SHF-P 
are included in Table 1.
In 1998, results were published from the first clinical 
trial to investigate SFH-P23 and, since then, Northfield has 
completed two Phase II and one Phase III trial to assess 
SFH-P. Northfield completed enrollment for PolyHeme’s 
Phase III trials in July 2006 and reported results from 
those trials in late 2006 and mid 2007.24, 25 These results are 
discussed in the next section.
HBOC-201/Hemopure (Biopure): Biopure, located 
in Cambridge, MA, developed Hemopure (hemoglobin 
glutamer-250, HBOC-201), which is produced from highly 
purified bovine hemoglobin. HBOC-201 is Hemopure’s 
third-generation product; the company had previously 
developed two other solutions that were explored through 
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various pharmacological studies.26 The first generation 
solution, Hemopure 1 Solution (H1S, Polymerized Bovine 
Hemoglobin), composed of 50% tetrameric hemoglobin and 
was used in a Phase I safety study, however its development 
was abandoned because patients experienced unacceptable 
gastrointestinal problems.27 Hemopure 2 Solution (HBOC-
301, Oxyglobin) was Biopure’s next-generation product. 
Its properties are similar to those of HBOC-201, with a 
lower average molecular weight.26 In 1998, Oxyglobin was 
approved for veterinary use, with a primary indication of 
managing canine anemia. Oxyglobin continues to receive 
significant enthusiasm from many veterinarians.28
HBOC-201 is Hemopure’s current product for human 
use and has undergone both animal studies and extensive 
clinical testing. A July 2007 Medline search using keywords 
“HBOC-201” or “Hemopure” returned 21 clinical, 44 
animal and 15 in vitro publications. HBOC-201 is derived 
from bovine hemoglobin, polymerized with glutaraldehyde. 
The solution is ultrapurified, which removes or inactivates 
potential contaminants such as cellular stroma, infectious 
agents and endotoxins.26 The final product’s hemoglobin 
concentration is 13 g/dL, which is the highest concentration 
of the three formulations. HBOC-201’s P50 is 40 mmHg, 
resulting in a lower oxygen affinity than native hemoglobin 
and the lowest P50 of the three solutions. Additionally it 
exhibits the highest methemoglobin percentage and the 
heaviest average weight of the three products. It also has the 
longest shelf life and can be stored at the widest range of 
temperatures.26 Additional characteristics of HBOC-201 are 
included in Table 1.
Key Clinical Trials
Tables 2, 3, and 4 summarize the key Phase II and III 
trials for HemAssist, PolyHeme, and Hemopure. Several 
smaller trials are not listed or discussed because they are 
either interim studies or have a very small patient population. 
We list the primary conclusions from the published studies 
and we only report physiologic effects that were statistically 
significant. We report all results on blood sparing and any 
other major clinical finding as reported by the authors, 
regardless of their statistical significance.
DCLHb/HemAssist (Baxter): HemAssist showed both 
promise and problems when studied in over 20 perioperative 
Table 2 - HemAssist clinical trials
Patient Population Control Dosage HBOC Dosage Physiologic Effects Treatment Effects
Surgical Patients15 Allogeneic PRBC transfusion 
(n=105), Up to 3Ua
(n=104), Up to 3U  ↑ MAP, SVR, Mean PAP, PVR
↓ CO, HR
↓ Day 1 PRBC use*
Stroke
Patients29
Saline (n=45),
25 –100 mg/kg
(n=40), 25 - 100 mg/kg  ↑ MAP  ↑ jaundice*, hemoglobinuria*
↓ Three month outcome*
Surgical Patients30 Allogeneic PRBC transfusion 
(n=84), Up to 3U
(n=89), Up to 3U None reported  ↑ jaundice*, urinary problems*, 
pancreatitis
↓ PRBC use through Day 7*
Terminated early
Trauma Patients32 Normal Saline (n=46),
500 - 1000mL
(n=52),
2 – 4U
None reported  ↑ mortality*
Terminated early
Trauma Patients34 Standard hemorrhagic shock 
resuscitation fluidsb (n=62), PRN
(n=53), Up to 2U None reported ↓ PRBC use
Terminated early
a 1U = 250 mL. b Standard hemorrhagic shock resuscitation fluids included volume expanders, crystalloids, colloids, plasma, blood, and vasopressors. 
* = p<0.05; all physiologic effects were reported as statistically significant per authors’ criteria. MAP = mean arterial pressure, SVR = systemic vascular 
resistance, PAP = pulmonary arterial pressure, PVR = pulmonary vascular resistance, PRBC = packed red blood cells
Table 3 - PolyHeme clinical trials 
Patient Population Control Dosage HBOC Dosage Physiologic Effects Treatment Effects
Surgical/Trauma Patients23 Allogeneic PRBC transfusion 
(n=23), PRN
(n=21), Up to 6Ua None reported Maintained total [Hb], but not RBC [Hb]*
Trauma Patients35 Historical controls, declined 
transfusions
(n=171), Up to 20U None reported Maintained total [Hb], but not RBC [Hb]
Trauma Patients25 Standard hemorrhagic shock 
resuscitation fluidsb (n=307), PRN
(n=279), Up to 6U None reported  ↑ cardiac adverse effects
↓ PRBC use
a 1U = 250 mL; b Standard hemorrhagic shock resuscitation fluids included volume expanders, crystalloids, colloids, plasma, blood, and vasopressors. 
* = p<0.05. Hb = hemoglobin, RBC = red blood cells, PRBC = packed red blood cells
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and intensive care unit (ICU) setting. The key clinical trials 
that evaluated HemAssist are listed in Table 2. One study 
compared HemAssist to PRBC in 209 postoperative cardiac 
bypass surgery patients.15 The patients received up to three 
250 mL infusions of HemAssist or PRBCs. The HemAssist 
group exhibited increased systemic and pulmonary vascular 
resistances and pressures compared with the control group. 
Mortality was similar in both groups. About 1 in 5, or 
19%, of the patients in the HemAssist completely avoided 
exposure to PRBCs. Although patients in the HemAssist 
group received significantly less PRBC units on day 0 and 
day 1 post surgery, a significant reduction in the total number 
of PRBCs administered was not observed because the 
HemAssist patients did not cumulatively receive less blood 
products over the course of the study. 
A study of 85 patients who had experienced acute 
ischemic stroke evaluated the use of HemAssist within 18 
hours of the onset of symptoms. Normal saline was used as 
the control.29 The researchers administered HemAssist in 
12 doses of 25, 50 or 100 mg/kg over 72 hours, resulting in 
an increase in mean arterial pressure from 113±14 mmHg 
to 134±20 mmHg, versus no increase in saline controls. 
The patients were evaluated at three months. Severe stroke 
at baseline and treatment with DCLHb showed to be 
independent predictors of an unfavorable outcome, based 
upon the Rankin scale. Thirty-four (85%) patients in the 
HemAssist group had an unfavorable outcome, as opposed 
to 23 (51%) in the control groups. 
A multicenter trial compared HemAssist against PRBC 
in 181 patients undergoing elective surgery.30 Patients 
received up to three 250 mL of either HemAssist or PRBCs. 
Blood sparing was possible in 23% of the HemAssist 
patients. However, the HemAssist-treated patients were also 
more likely to suffer from adverse effects. Because of safety 
concerns, the study was terminated early.
In 1997, Baxter launched their final, pivotal study, 
testing HemAssist on patients in ambulance and emergency 
departments (ED) in both the United States and Europe. 
The first trial conducted under the FDA’s exception from 
informed consent for emergency research (21 CFR 50.24). 
For the U.S. trial, the investigators planned to enroll 
850 patients in the study from 35 trauma centers across 
the U.S. to determine whether the solution resulted in a 
decrease in the 28 day mortality.31 The study was designed 
as a randomized, single blinded efficacy trial of patients 
with traumatic hemorrhagic shock and unstable vitals. 
Patients were to receive either 500 mL of HemAssist 
or normal saline.32 In 1998, the trial’s independent data 
monitoring committee performed an interim data review 
after approximately 100 patients had been enrolled.33 
HemAssist was found to be significantly less effective than 
the standard of care and the study was terminated. Of the 52 
patients infused with HemAssist, 24 (46%) died, whereas 
only 8 (17%) of the 46 saline patients died. The cause for the 
increased mortality could not be established from that data. 
However, researchers speculated that it was a result of the 
known vasopressor effects of hemoglobin solutions. 
Baxter had also initiated a separate study in Europe 
around that time. A study involving 121 patients suffering 
from severe hemorrhagic shock examined the use of 
HemAssist in reducing MOF from tissue hypoxia.34 The 
groups received either up to 1000 mL of 10% HemAssist 
solution or the study center’s standard therapy. However, 
the study was prematurely terminated because HemAssist 
did not significantly reduce rates of organ failure and 
because researchers could not offset other concerns 
raised about HemAssist’s safety record during the U.S. 
trial. Because of these problems, commercial production 
of HemAssist ceased. Baxter evaluated recombinant 
hemoglobin formulations for a several more years and 
eventually terminated its HBOC program.
SFH-P/PolyHeme (Northfield): The first prospective, 
Table 4 - Hemopure clinical trials
Patient Population Control Dosage HBOC Dosage Physiologic Effects Treatment Effect
Surgical Patients38 Allogeneic PRBC transfusion
(n=24), PRN
(n=40), 60g, option of 3 more 
doses of 30g
 ↑ MAP, serum urea [N2], Bicar-
bonate, BE, plasma [Hb]
↓ Hct
↓ PRBC use in 27% of 
patients
Surgical Patients39 Allogeneic PRBC transfusion
(n=48), PRN
(n=50), 60g, option of 3 more 
doses of 30g
 ↑ MAP, Mean PAP, arterial O2 ↓ CI, SpO2
 ↑ O2 extraction*↓ PRBC use
Surgical Patients40 LR
(n=26), 849 mL
(n=55), 
0.6g/kg - 2.5g/kg
 ↑ plasma Hb Intraoperative use of 
HBOC well tolerated
Surgical Patients42 Allogeneic PRBC transfusion 
(n=338), PRN
(n=350), 65g, up to 325g  ↑ total [Hb], Hct  ↑ cardiac adverse effects*
↓ PRBC use*
*
 = p<0.05; all physiologic effects reported as statistically significant per the authors’ criteria, LR= lactated Ringer’s solution, RBC= red blood cells, 
PRBC= packed red blood cells, MAP= mean arterial pressure, BE= base excess, Hb= hemoglobin, Hct= hematocrit, PAP= pulmonary arterial pressure, 
CI= cardiac index
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randomized study using PolyHeme23 evaluated its safety 
and therapeutic benefits compared to allogeneic red blood 
transfusion. Forty-four trauma patients were randomized, 
with 23 receiving PRBC and 21 receiving up to 6 units of 
PolyHeme (4.4 ± 2.0 units). Adverse events or safety issues 
were not reported for PolyHeme, suggesting it was well-
tolerated in this setting. PolyHeme maintained hemoglobin 
concentration and reduced the need for allogeneic blood by 
approximately 3.5 units. 
Another large study compared 171 trauma patients who 
received PolyHeme during surgery to a historical control 
group of 300 patients who refused red cells for religious 
reasons.35 The PolyHeme patients received up to 20 units and 
the study compared their 30 day mortality rates against the 
control. PolyHeme maintained total hemoglobin concentration 
in the 7 to 10 g/dL range and the mortality rate in this group 
was 25%, compared with a mortality rate of 65% in the 
historical control group. However, the U.S. Food and Drug 
Administration (FDA) made it clear that they would not 
accept historical control data as a Phase III clinical trial. A 
large multicenter, pre-hospital/emergency department study 
of PolyHeme was subsequently launched 2003.
In December 2006, Northfield announced in a press 
release it had completed enrollment in its Phase III clinical 
trial. At the same time, the company released preliminary 
data.24 Northfield reported more detailed results of the 
study in May 2007.25 The study included 586 patients 
with traumatic hemorrhagic shock, of whom 279 received 
PolyHeme and 307 received the hospital’s standard of care. 
Thirty-one (11.1%) of the PolyHeme patients died, while 28 
(9.1%) of the control patients died by the time the Day 30 
mortality analysis was performed. In the PolyHeme group, 
41% of the patients received additional PRBC transfusions, 
while 51% in the control group received additional blood. 
With regard to other safety data, 93% of the patients in the 
PolyHeme group and 88% of the patients in the control 
group experienced adverse effects, which largely consisted 
of anemia, fever, and electrolyte imbalance. In May 2009, 
the FDA refused to approve PolyHeme and in June 2009, 
Northfield filed for bankruptcy under the Chapter 11 
Bankruptcy Code.
HBOC-201/Hemopure (Biopure): Key trials for Biopure 
are listed in Table 4. An early clinical study with Hemopure 
patients undergoing elective abdominal surgery illustrated a 
key physiologic function of HBOCs.36 The study examined 
Hemopure’s effect on hemodynamics and oxygen transport. 
The patients received either 3 mL/kg of Hemopure or 6% 
hydroxyethyl starch (HES) over 30 minutes and invasive 
arterial pressures, blood gases and cardiac index, vascular 
resistance, oxygen delivery, oxygen consumption, and 
oxygen extraction were monitored. Because of the reported 
increase in mean arterial pressure and systemic vascular 
resistance, as well as the notable decrease in cardiac index, 
the authors concluded that Hemopure impaired oxygen 
delivery because it induced a reduction in cardiac output. 
Similar results (impaired cardiac output despite the expected 
volume expansion) have also been reported for HemAssist 
and PolyHeme.37,19 
Another intraoperative study evaluated 72 patients 
undergoing infrarenal aortic reconstruction, randomized in 
a 2 to 1 ratio to receive either Hemopure or red blood cell 
transfusions.38 Patients in the Hemopure group received 60 g 
of Hemopure as an initial transfusion, with up to 3 additional 
doses (30 g each) administered within 96 hours at the 
discretion of the treating physician. Hemopure eliminated 
the need for additional PRBC infusions in 27% of the treated 
patients but did not reduce the mean PRBC requirement of 
the patients who received it. It also caused a 15% increase in 
mean arterial pressure.
A randomized, double-blind trial of Hemopure evaluated 
its efficacy as an alternative to red blood cell transfusion.39 
The study included 98 patients undergoing cardiac surgery, 
who were randomly assigned to receive Hemopure or red 
blood cells for the first three postoperative transfusions. 
The Hemopure patients received 60 g of Hemopure in 
500 mL for the initial transfusion and up to two additional 
infusions of 30 g in 250 mL over the next 72 hours. 
Although Hemopure lowered cardiac index, it eliminated 
any additional RBC transfusions in 34% of the patients who 
received it and it appeared to maintain oxygen transport. 
In a randomized, single-blinded trial, the tolerability 
of a single dose of Hemopure was evaluated.40 The study 
included 81 surgical patients, who were randomized to 
receive either lactated Ringer’s solution or a single infusion 
of Hemopure, both in doses of 0.6, 0.9, 1.2, 1.5, 2.0 or 
2.5 mL/kg. After evaluating Hemopure’s effects on blood 
chemistry, hemoglobin concentration, methemoglobin 
concentration, urine output and pressure, the authors 
concluded that Hemopure was generally well-tolerated. 
However patients’ blood pressures were slightly, but 
consistently, higher in the Hemopure group.
In December 2006, the FDA denied Biopure’s 
application to study Hemopure in a Phase III trauma 
trial and recommended it undergo a pre-hospital Phase II 
study to evaluate its safety and efficacy in a study with a 
smaller patient population.41 Biopure recently published 
the results of their Phase III study evaluating Hemopure’s 
ability to reduce or eliminate perioperative transfusion 
in orthopedic surgical patients.42 The study included 688 
patients randomized to receive either Hemopure or PRBCs. 
The Hemopure patients received up to 325g of Hemopure in 
2,500 mL over a maximum of six days. Any additional blood 
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requirements were met with PRBCs. The control group was 
administered PRBCs as needed. Hemopure reduced the need 
for additional blood transfusions in 59% of the patients. 
However, the rate of adverse effects in the Hemopure group 
was significantly higher.
Although the FDA has not approved Hemopure, South 
Africa’s Medicine Control Council issued its approval of 
the product in April 2001 for use in acutely anemic patients. 
43
 This is particularly important because of the continuing 
HIV problem in South Africa. An HBOC can provide a 
safe transfusion alternative to donated blood, which may be 
infected with HIV. 
Ethical Issues Regarding HBOC Clinical Trials
Perhaps because of the ambiguous results that resulted 
from the perioperative and ICU trials, all three companies 
elected to perform their Phase III trials in the pre-hospital 
trauma setting. They chose to do this because blood is not 
available during the pre-hospital period and therefore the 
investigators thought the rapid delivery of HBOCs may have 
the greatest impact on survival in this setting. The rationale 
for the setting was the potential that these HBOCs could 
potentially save more lives than were lost in the emergent 
trauma setting and that they could significantly reduce the 
number of transfusions required by patients. The PolyHeme 
trial was designed as a superiority/non-inferiority study, 
which aimed to demonstrate that PolyHeme was at least as 
effective as or possibly better than standard treatment. The 
FDA considers non-inferiority trials to be an acceptable study 
design and an acceptable marketing base for companies.
The recently completed Northfield trial showed that 
mortality was not significantly different between groups, 
despite a 22% higher mortality rate with PolyHeme (11.1%) 
versus the control group (9.1%).25 The requirement for 
autologous blood was reduced from 51% to 41%, in the 
control group and the PolyHeme group respectively. 
If approved, a safe HBOC could change the way 
transfusion medicine is practiced and possibly reduce 
the morbidity and mortality of major surgical procedures 
and trauma. HBOCs have the potential to reduce the 
incidence of inflammatory effects that result from trauma 
and transfusions, as well as preventing other problems 
associated with transfusions. However, trials to evaluate 
HBOCs have impacted the healthcare community at 
the junction where clinical practices and societal ethics 
meet. For the Phase III trial that completed enrollment 
in December 2006, PolyHeme enrolled its patients under 
a rule established by the FDA in 1996, which waives 
informed consent in life-threatening conditions that must 
be handled quickly and when no better alternative is 
available.44 The PolyHeme trial enlisted the 32 Level 1 
Trauma centers in 18 states and patients in hemorrhagic 
shock received either the hospital’s normal standard of 
treatment or PolyHeme.24 The study design produced 
several problems.45 The waived informed consent rule that 
Northfield used to enroll patients concerned many ethicists 
and community leaders. Investigators were required 
to educate their communities about the trial, through a 
variety of means. People within the communities could 
then decide to “opt out” of the trial by wearing colored 
bracelets, indicating they did not want to participate in the 
study if they were subsequently injured and unable to give 
consent. Educating the public about the study was difficult 
for a variety of reasons, such as limited budgets and lack of 
guidelines for informing the public about the study. 
Another ethical criticism of the study was aimed at the 
study design. Patients in the PolyHeme group received 
their initial dose while in the ambulance, on the way to 
the hospital, whereas the control subjects were given a 
crystalloid solution. However, once inside the ED, the 
control patients were given blood transfusions, while the 
PolyHeme patients continued to receive the test solution 
for the next 12 hours instead of blood. The waived 
informed consent rule stipulated that in order for the rule 
to be used, “available treatments…[must be] unproven or 
unsatisfactory.”44 The study complied with this provision 
while PolyHeme subjects were in the ambulance, since 
ambulances do not carry blood and instead administer 
crystalloid. Unlike HBOCs, crystalloid fluids possess no 
oxygen carrying capacities and are used to simply maintain 
blood volume in trauma patients. However, ethicists 
suggested the conditions allowing the waiver of informed 
consent was then violated once the patients reached the 
ED because the PolyHeme subjects failed to receive blood 
and instead continued to receive the test solution.46 They 
contended that since blood is readily available in the ED 
and is a proven therapy, the use of PolyHeme in the ED was 
unethical because patients were not given blood, but instead 
received an experimental treatment. 
The need for an effective study design that both follows 
the scientific process and complies with community ethical 
standards is essential for the continued evaluation of any 
HBOC product. Society must determine how much risk the 
population will accept to save lives in the short term and 
to reduce mortality in the future. Inherent in any research 
endeavor is the problem of risk, and communities must 
weigh the possible benefits of the study against its possible 
risks. However, these communities must be fully educated 
about the study and investigators must make every effort to 
inform the communities in which the study will be carried 
out about the trial. 
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Meta-analysis
A recent meta-analysis published by Natanson et al. 
examined the overall mortality rates of the three HBOCs 
we reviewed, as well as a few other HBOCs, and all were 
combined as a product class.47 The study found that patients 
treated with an HBOC had a 30% increased risk of mortality 
and a 2.7-fold increase for myocardial infarction. Further 
analyses indicate that these increased risks are consistent 
across patient population or specific product type. Because 
of these findings, Natanson et al. argue for preclinical animal 
studies of any existing or developing HBOCs in order to test 
for known toxicities. We suggest such studies must have a 
priori set endpoints and should be conducted by independent 
groups with FDA regulatory oversight.
The study also criticizes the lack of timely data put forth 
by the companies and the lack of published studies. Both 
Hemopure and Polyheme published studies only several 
years after the completion of their trials. Additionally, 
unpublished studies render a thorough IRB review of trials 
difficult. Natanson et al. argue for the timely and complete 
disclosure of data to the scientific community to avoid 
exposing the public to unnecessary risks.
Biopure responded to the Natanson et al. meta-analysis 
by claiming the authors made fundamental errors when 
analyzing the data and claimed the meta-analysis was 
inappropriately applied.48 Biopure also claimed there were 
errors in the authors’ calculations, and also stated that the 
products chosen for inclusion in the meta-analysis were 
inappropriately grouped and generalized.
New HBOCs in Development
Other companies, such as HemoBioTech, Sangart, 
and Oxygenix are currently working to develop HBOCs, 
but have not reported data from U.S. clinical trials. 
HemoTech was developed by HemoBioTech and derived 
from bovine hemoglobin. It underwent foreign pre-clinical 
and clinical testing in the late 1980s and early 1990s.49 
At the time of writing, HemoBioTech, in conjunction 
with Paragon Biomedical, is pursuing clinical trials in 
India. Sangart produces Hemospan, which is derived from 
human hemoglobin that has been chemically modified 
by attaching polyethylene glycol polymers its surface.50 
Sangart is conducting Phase II trials in the U.S. and 
Phase III trials in Europe. Using a different approach to 
modifying hemoglobin, the U.S. Navy began researching 
liposome-encapsulated hemoglobin, or neo red cells. This 
unique oxygen carrier is being developed by Oxygenix, 
the company that produces Oxy-0301, and is still in the 
experimental phase.51
SUMMARY
Based on the results of clinical results, the efforts 
of Baxter, Northfield and Biopure to develop a safe and 
effective HBOC have not met with success to date. Tables 
2-4 demonstrate both the potential and the limitations of 
the HBOCs reviewed. In some studies, the HBOCs did 
significantly decrease or eliminate the need for PRBC 
transfusions. Alarmingly, they also resulted in greater 
incidences of adverse side effects including pulmonary 
hypertension and cardiac depression. Our analysis and the 
conclusions of these studies suggest that the risks of using 
HBOCs currently exceed the benefits. It does not seem 
likely that any of these products will become successful in 
their present formulation until these unwanted effects are 
resolved. Despite many setbacks in the development of its 
product, Biopure continues to work towards FDA approval. 
The quest for the Holy Grail of blood substitutes remains 
unfulfilled. To succeed, investigators must overcome 
scientific barriers, as well as federal regulation and social 
apprehension. However, if such a product can be developed, 
it will dramatically change both surgical and critical care 
medicine. 
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